Circulating sex hormones and risk of atrial fibrillation: A systematic review and meta-analysis

Peng Hu1,2†, Jun Huang3†, Yi Lu4†, Murui Zheng5, Haiyi Li6, Xueru Duan1, Hai Deng7*, Wenjing Zhao8* and Xudong Liu2*

1Department of Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou, China, 2School of Public Health, Guangdong Pharmaceutical University, Guangzhou, China, 3Department of Geriatrics, Institute of Geriatrics, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Science, Guangzhou, China, 4Health Effects Institute, Boston, MA, United States, 5Guangzhou Center for Disease Control and Prevention, Guangzhou, China, 6Shantou University Medical College, Shantou, China, 7Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Science, Guangzhou, China, 8School of Public Health and Emergency Management, Southern University of Science and Technology, Shenzhen, China

Background: Sex hormones are associated with many cardiovascular risk factors, but their effects on atrial fibrillation (AF) incidence remain unclear. This systematic review and meta-analysis aimed to evaluate the association of circulating sex hormones with AF risk by pooling available data from observational studies.

Methods: A systematic literature search for pertinent articles with case-control and cohort designs was conducted via five databases up to 7 July 2021. A meta-analysis with six cohort studies was conducted separately on men and women. Adjusted relative risk (RR) with a 95% confidence interval (CI) was derived by comparing the highest with the lowest levels of a specific sex hormone and by using a random-effect or fixed-effect model. Heterogeneity was tested using the $I^2$ statistic and the Q-test.

Results: A total of six cohort studies and four case-control studies were included. In a meta-analysis of cohort studies, dehydroepiandrosterone sulfate (DHEAS) was associated with a decreased risk of AF in men (RR: 0.729, 95% CI: 0.559–0.952, $I^2 = 50.0\%$, $P_{\text{heterogeneity}} = 0.157$) after combining results from two cohort studies; total testosterone was not associated with any risk of AF in men and postmenopausal women, and AF risk was not associated with estradiol in men after synthesizing available studies.

Conclusion: This study indicates that a higher endogenous DHEAS level was associated with a lower AF risk in men, whereas total testosterone and estradiol were not associated with AF risk. Longitudinal studies with multiple
monitoring are needed to further promulgate the relationship between various circulating sex hormones and AF risk.

KEYWORDS
sex hormones, atrial fibrillation, total testosterone, estradiol, dehydroepiandrosterone sulfate

Introduction

Atrial fibrillation (AF) is the most common cardiac arrhythmia. Its incidence and prevalence increased during the past two decades and will continue to increase in the next 10 years (1, 2). AF is the common cause of cardioembolic stroke and heart-related hospitalizations, resulting in severe mortality and disability (3, 4). Studies from different regions suggested that the incidence of AF increased with advancing age and tended to be higher in men than in women (5–7); however, compared with men, women showed more severe atypical symptoms and poorer quality of life, as well as a higher risk of adverse events, such as stroke and death associated with AF (8, 9).

Gender-related endogenous sex hormones have gotten much more attention recently and were reported to be associated with cardiovascular risk factors, such as hypertension (10), obesity (11, 12), and type 2 diabetes mellitus (13, 14). Cardiac myocytes could express estrogen and androgen receptors, indicating that sex hormones might influence ion channels and their expression and finally affect the heart rhythm (15, 16). However, the current epidemiological evidence about the associations of sex hormones with the incidence of AF is inconsistent. For instance, Zeller et al. found that low serum total testosterone (TT) concentration was associated with an increased risk of AF in men (17), while Berger et al. reported a positive association of plasma testosterone level with the incidence of AF in men (18); estradiol produced from testosterone aromatization is linked to AF risk (19), but this was inconsistent with other studies (20–22).

Until now, the association of circulating sex hormones with AF risk remains unclear. Thereafter, we conducted this systematic review with meta-analysis in light of MOOSE guidelines (23) to examine the association between circulating sex hormones and AF risk.

Materials and methods

Search strategy and selection criteria

Up to 7 July 2021, five electronic databases, including PubMed, Embase, Web of Science, Chinese National Knowledge Infrastructure (CNKI), and WANFANG DATA, were searched. The following key words were used: “sex hormone,” “gonadal steroid hormones,” “estrogen,” “oestrogen,” “estradiol,” “oestradiol,” “progestins,” “progestagens,” “progestational hormones,” “progestogens,” “progesterone,” “androgen,” “testosterone,” “dehydroepiandrosterone sulfate,” “follicle stimulating hormone,” “luteinizing hormone,” “prolactin,” “androstenedione,” “sex hormone binding globulin,” “atrial fibrillation,” and “auricular fibrillation.” Details of the search strategy are shown in Supplementary Table 1. Citation and reference tracking through both Scopus and Web of Science were also used to identify studies.

Two researchers (PH and WZ) conducted the literature search independently, reviewed, and identified relevant literature. Disagreements were resolved by group discussions with the third researcher (XL). Studies that met the following criteria were included: (1) case-control studies or cohort studies; (2) the serum or plasm levels of TT, bioavailable testosterone (BT), estradiol, dehydroepiandrosterone sulfate (DHEAS), free dihydrotestosterone (DHT), and sex hormone binding globulin (SHBG) were detected; (3) published in English or Chinese; (4) effect estimates (including odds ratio, relative risk (RR), and hazard ratio) and 95% confidence intervals (95% CI) were reported or they can be calculated according to the reported data. Studies were excluded if they were duplicated studies, cross-sectional studies, case reports, animal studies, in vitro and in vivo experiments, reviews, editorials, comments, abstracts, effect estimates were not reported or could not be calculated, and studies in neither English nor Chinese.

Data extraction

Detailed information from each study was extracted, and the information included the first author, publication year, study design, sample size, country in which the study was conducted, age, gender, sex hormone detection method, whether to take samples after fasting, whether to exclude subjects with hormone therapy, confounding factor for multivariable analysis, body mass index, median or mean of follow-up years for the cohort study, effect calculating approach, and specific sex hormone. The effect estimates and 95% CIs for each specific sex hormone obtained from the multivariable model were also extracted.
The quality of each study was assessed using the Newcastle-Ottawa Scale (NOS) criteria for the included cohort studies or case-control studies (24). The maximum total score is nine stars: four stars for selection, two stars for comparability, and three stars for assessment of outcomes or exposures. The studies were classified as high quality (7–9 stars), moderate quality (4–6 stars), and low quality (0–3 stars) in terms of the total scores.

Statistical analysis

A systematic review was conducted among cohort and case-control studies, and the meta-analysis was only conducted among cohort studies as the cause-and-effect timing sequence cannot be determined among case-control studies. The RR was used to uniformly display the pooled effect of cohort studies in this study. A meta-analysis was conducted separately in men and in women to generate the pooled RR for each specific sex hormone. The pooled RR with 95% CI was derived by comparing the highest sex hormone levels with the lowest and by using a random-effect or fixed-effect model. The effect estimates in Magnani’s report (20) were calculated by comparing the lowest and highest tertiles, through the approach suggested by Danesh et al. (26). These effect estimates used for pooled analysis were reckoned by multiplying 2.18 with the log-transformed transformed to the effect obtained by comparing the highest sex hormone. The pooled RR with 95% CI was derived by comparing the highest sex hormone levels with the lowest tertiles, through the approach suggested by Danesh et al. (26). These effect estimates used for pooled analysis were reckoned by multiplying 2.18 with the log-transformed

The $I^2$ statistic and the Q-test were used to examine the heterogeneity. The $I^2$ value of more than 50% or $P$-value from the Q-test of less than 0.1 suggested significant heterogeneity (27). A random-effect model was adopted if there was significant heterogeneity; otherwise, a fixed-effect model was selected. To seek the sources of heterogeneity and to examine the robustness of the main results, subgroup analysis was conducted based on several study characteristics: region (United States, non-United States), age (<63 years, ≥63 years), body mass index (<27.5 kg/m$^2$, ≥27.5 kg/m$^2$), and TT assessment method (radioimmunoassay, others: liquid chromatography-tandem mass spectrometry, chemiluminescent microparticle immunoassay). A random-effects meta-regression analysis was also conducted to estimate these characteristics for the potential sources of heterogeneity in this study. Repeated analysis was conducted to examine the contribution of each study to the pooled estimates by omitting one study at a time. The publication bias was illustrated by using the funnel plot and Begg’s test. An asymmetric funnel plot or a $P$-value of Begg’s test of lower than 0.05 was considered to have significant publication bias. All statistical analyses were conducted using the Stata 12.0 software (Stata Corporation, College Station, TX, United States).

Results

Systematic review

The flowchart of study selection is shown in Figure 1. A total of 3,979 articles were searched from five databases. Approximately 1,174 articles were excluded for duplication, and 2,780 were excluded after the screening of titles and abstracts. Among the twelve articles retained for further full-text review, two articles focused on the same population and reported similar results to another two articles, respectively; hence, only two recently published articles were selected. Finally, six cohort studies (17, 18, 20, 21, 28, 29) and four case-control studies (22, 30–32) were included in this systematic review, and six cohort studies (17, 18, 20, 21, 28, 29) were selected for meta-analysis. The NOS was used to evaluate the quality of studies included (Supplementary Table 2). All selected studies had moderate to high quality, and the quality score for cohort studies ranged from 7 to 9, and for case-control studies, it ranged from 5 to 7.

The general characteristics of the 10 selected studies are shown in Tables 1, 2, and the main sex hormones measured in the included studies are shown in Tables 3, 4. All four case-control studies were conducted in China (22, 30–32); three studies focused on both estradiol and TT, and one study only focused on TT. For included cohort studies, four came from the United States (18, 20, 21, 28), one from the Netherlands (29), and one from Finland (17); four studies in men (17, 18, 20, 21) and three studies in menopausal women (17, 18, 21) focused on TT; two studies in men (20, 21) and one study in post-menopausal women (21) on estradiol; two studies in men on DHEAS (20, 29); one study in men on free DHT (28), one study on BT (21), and one study on SHBG (21); the median or mean of follow-up years of six cohort studies ranged from 9.5 to 13.8 years.

For all ten studies, the average BMI in men ranged from 24.12 to 28.00 kg/m$^2$, and the average BMI in post-menopausal women varied from 24.08 to 29.00 kg/m$^2$. Among them, four studies (17, 21, 31, 32) excluded the individuals receiving sex hormone therapy, whereas the other six (18, 20, 22, 28–30) never did that. For the detection of sex hormones, three cohort studies (17, 21, 28) and three case-control studies (22, 31, 32) collected fasting blood samples. Circulating TT concentration was detected by using radioimmunoassay in three studies (20–22), chemiluminescent microparticle immunoassay in four studies (17, 30–32), and liquid chromatography-tandem mass spectrometry assay in one study (28). Estradiol concentration was measured by radioimmunoassay in three studies (20–22) and the chemiluminescence method in two studies (31, 32). DHEAS concentration was measured by radioimmunoassay in both studies (20, 29).
Confounders adjusted in each study were different. Age was used as a confounding factor in eight studies (17, 18, 21, 22, 29–32), and stratified analysis was conducted by age in two studies (20, 28). Body mass index was used as a confounding factor in seven studies (18, 20–22, 28, 29, 31), while the other three (17, 30, 32) did not do this. All six cohort studies used the smoking status as a confounding factor, but four case-control studies did not use smoking status as a confounding factor.

Among the included cohort studies that revealed the associations between TT level and AF risk, in men, one study showed that TT level was associated with increased AF risk (18), two studies showed TT level was associated with decreased risk of AF (17, 20), and one study did not find a significant association between TT level and AF risk (21); in post-menopausal women, two studies found TT level was not significantly associated with AF risk (18, 21), and one study showed that TT level was positively associated with AF risk (17).

The association between estradiol and DHEAS level with AF risk was revealed in two cohort studies, respectively. In men and post-menopausal women, one study showed that estradiol level was not significantly associated with AF risk (21), and in men, one study showed that estradiol level was associated with a lower risk of AF (20). In men and post-menopausal women, one study showed that DHEAS was associated with a decreased risk of AF (29), while one study showed that DHEAS level was not significantly associated with AF risk in men (20). In addition, one study showed that a low level of DHT was associated with an increased risk of AF risk in men (28); one study found that BT level was associated with increased AF risk in men, whereas no association was observed in post-menopausal women (21); one study showed that SHBG was not associated with any AF risk in men and women (21).

Among the included case-control studies, two studies showed that testosterone level was associated with a decreased AF risk in men (30, 32), and one study did not show an association between testosterone level and AF risk in men (22); two studies showed estradiol level was not significantly associated with AF risk in men (22, 32). Only one case-control study was conducted in post-menopausal women and did not find a significant association between testosterone and estradiol levels with AF risk (31).

Meta-analysis of cohort studies

Total testosterone level and atrial fibrillation risk in men

As shown in Figure 2A, TT concentration was not associated with the risk of AF in men when results from four original studies were synthesized (RR: 1.008, 95% CI:
| Reference, country | Study design | Total samples (men/women), n | Outcome (men/women), n | Age, years | Follow-up years | BMI | Morning blood samples | Whether to take samples after fasting | Whether to exclude subjects with hormones therapy | Circulating sex hormones detection method | Effect estimator calculation method |
|-------------------|-------------|-----------------------------|------------------------|------------|----------------|-----|----------------------|-------------------------------------|---------------------------------|------------------------------------------|-----------------------------------|
| Rosenberg et al. (28), United States | Longitudinal cohort | 1,019 (1,019/–) | AF 304 (304/–) | 76.3 ± 4.9 | 9.5 years | 26.7 ± 3.7 | Not mention | Yes | No | TT and DHT: liquid chromatography–tandem mass spectrometry assay; SHBG: time-resolved fluoro-immunoassay; free testosterone and free DHT: Mazer method | Cox proportional hazards regression model |
| Berger et al. (18), United States | Prospective cohort study: Atherosclerosis Risk in Communities (ARIC) study | 9,282 (4,224/5,058) | AF 1490 (772/718) | All 63 (range 52–75) | 13.7 years | Male 28 ± 4.5; female 29 ± 6.2 | Yes | Not mention | No | TT: liquid chromatography tandem mass spectrometry | Cox regression models |
| Krijthe et al. (29), Netherlands | Population-based prospective cohort study (The Rotterdam Study) | 1,180 (547/633) | AF 129 (67/62) | 69 ± 8.4 | 12.3 years | 26.1 ± 3.4 | Not mention | No | No | DHEAS: coated tube radioimmunoassays | Cox proportional hazards analyses |
| Magnani et al. (20), United States | Prospective, community-based cohort study (The Framingham Heart Study) | 1,251 (1,251/–) | AF 275 (275/–) | 68.0 ± 8.2 | 10 years | 26.7 ± 3.8 | Not mention | Not mention | No | TT, estradiol, DHEAS: radioimmunoassays | Cox proportional hazards regression analyses |
| O’Neal et al. (21), United States | Population-based prospective cohort study (Multi-Ethnic Study) | 4,883 (3,003/1,880) | AF 613 (613/–) | All 63 ± 10 | 10.9 years | Male 28 ± 4.4; female 29 ± 6.1 | Not mention | Yes | Yes | TT: RIA kits SHBG: chemiluminescent enzyme immunometric assay using Immulite kits E2: ultrasensitive RIA kit BT: [total T × (percent-free T × 0.01)] | Cox regression |
| Zeller et al. (17), Finland | Population-based prospective cohort study (the FINRISK study) | 7,892 (3,876/4,016) | AF 426 and/or IST 276 | Men 49.2 (range 37.7–60.7) | 13.8 years | Male 26.6 (range 24.3–29.1); female 25.5 (range 22.7–29.1) | Not mention | Yes | Yes | TT: a chemiluminescent microparticle immunooassay (CMIA) | Cox regression |

*AF, atrial fibrillation; BMI, body mass index; BT, bioavailable testosterone; CI, confidence interval; DHEAS, dehydroepiandrosterone sulfate; DHT, dihydrotestosterone; HR, hazard ratio; IST, ischemic stroke; RIA, radioimmunoassay; SHBG, sex hormone binding globulin; TT, total testosterone.*
TABLE 2 General characteristics of the included case-control studies.

| Reference, Region | Sample size (cases/controls) | Age, years (case/control) | BMI (case/control) | Morning samples | Whether to take samples after fasting | Whether to exclude subjects with hormones | Sex hormone detection method | Effect estimator calculation method |
|-------------------|-----------------------------|--------------------------|-------------------|----------------|-------------------------------------|------------------------------------------|-------------------------------|-----------------------------------|
| Lian (30), Zhejiang, China | Case: 130 men, 76 women | 74 ± 52.68/75 ± 55.40 | 24.12 ± 2.02/24.16 ± 2.70 | Yes | No | No | Chemiluminescence method | Logistic regression analysis |
| Wei (32), Gansu, China | Case: 63 men, 76 women | 70 ± 49.54/72 ± 66.90 | 24.83 ± 2.74/24.55 ± 2.66 | Yes | Yes | Yes | Chemiluminescence method | Logistic regression analysis |
| Ma (31), Gansu, China | Case: 107 women, 72 women | 70 ± 66.07/75 ± 66.07 | 24.83 ± 2.74/24.83 ± 2.66 | Yes | Yes | Yes | Chemiluminescence method | Logistic regression analysis |
| Lai et al. (22), Zhejiang, China | Case: 58 men | 70.50 ± 7.50 | Control: 66.07 ± 8.10 | Not mention | Not mention | Not mention | Radioimmunoassay method | Analysis |

AF, atrial fibrillation; BMI, body mass index.

0.799–1.273, $I^2 = 83.1\%$, $P_{\text{heterogeneity}} < 0.001$). Similarly, no significant association was found in any other subgroups stratified by regions, age, body mass index, and TT detection method (Table 5). Sensitivity analysis was repeated four times by omitting one study each time, and no significant change in the pooled results was found (Supplementary Figure 1a and Supplementary Table 3).

Total testosterone level and atrial fibrillation risk in post-menopausal women

As shown in Figure 2B, TT level was not associated with AF risk in post-menopausal women when all three studies were pooled (RR: 1.069, 95% CI: 0.917–1.246), with lower heterogeneity ($I^2 = 49.1\%$, $P_{\text{heterogeneity}} = 0.140$). In sensitivity analysis, the pooled analysis was repeated three times by excluding one study each time, and no significant change was observed (Supplementary Figure 1b and Supplementary Table 3).

Estradiol level and atrial fibrillation risk in men

As shown in Figure 3A, no significant association of circulating estradiol levels with AF risk in men was observed when both studies were pooled (RR: 0.920, 95% CI: 0.663–1.277, $I^2 = 70.8\%$, $P_{\text{heterogeneity}} = 0.064$).

Dehydroepiandrosterone sulfate level and atrial fibrillation risk in men

When two cohort (20, 29) studies including 2,431 subjects and 404 AF cases were pooled (Figure 3B), a high level of circulating DHEAS was significantly associated with a decreased AF risk (RR: 0.729, 95% CI: 0.559–0.952), with a lower heterogeneity ($I^2 = 50.0\%$, $P_{\text{heterogeneity}} = 0.157$).

Publication bias

The funnel plots did not show any significant asymmetry (Figure 4). The Begg's test did not reveal any significant publication bias when examining the associations between TT levels and AF risk in men ($P = 0.734$) and in post-menopausal women ($P = 1.000$), the associations between estradiol levels and AF risk in men ($P = 1.000$), and the association between DHEAS levels and AF risk in men ($P = 1.000$).

Discussion

To the best of our knowledge, this systematic review and meta-analysis comprehensively examined the association of AF risk with circulating sex hormones. Based on the synthetization of limited evidence, the pooled results suggested that a higher level of DHEAS was associated with a lower risk of AF in men, whereas the association of AF risk with TT and estradiol was observed in neither men nor post-menopausal...
| Reference, country | Exposure details | Confounding factor for multivariable analyses | Specific sex hormone | Effect estimator | Transformation of effect estimator |
|-------------------|-----------------|-----------------------------------------------|----------------------|----------------|-----------------------------------|
| Rosenberg et al. (28), United States | Low free DHT (<0.16 ng/dl); the lowest quintile of values | Demographics (race, education, income, clinic location, and smoking status), clinical risk factors (BMI, standing height, DM, use of antihypertensive medications, SBP (mm Hg), depressed LV function, serum cystatin C level, and use of loop diuretics), left atrial diameter, and serum NT-proBNP levels | Free DHT | Q1 1.48 (1.01–2.17) 0.044 | – – – – |
|                        |                 |                                               | Q2-Q5 1 | – | – – – – |
| Berger et al. (18), United States | Testosterone levels were split into sex-specific quartiles: | Race, age, BMI, smoking status, estimated glomerular filtration rate, SBP, antihypertensive medication use, diabetes, prevalent coronary heart disease, and prevalent heart failure | Total testosterone | Q1 1.21 (0.99–1.48) | – – – – |
|                        | Men: | Q1: ≤388.62 ng/dl | Q2 1.17 (0.95–1.45) | Q3 0.99 (0.80–1.22) | – – – – |
|                        | Q2: 388.63–511.23 ng/dl | Q4 1.33 (1.07–1.66) | Q4 0.33 (0.14–0.80) | – | – – – – |
|                        | Q3: 511.24–659.25 ng/dl | Q4: > 659.25 ng/dl | Q4 0.33 (0.14–0.80) | – | – – – – |
|                        | Q4: > 659.25 ng/dl | Women: | Q1: ≤17.20 ng/dl | Q2 1.33 (1.07–1.66) | 0.99 (0.80–1.22) | – – – – |
|                        | Q2: 17.21–23.17 ng/dl | Q3: 23.18–31.55 ng/dl | Q4 1.33 (1.07–1.66) | Q4 0.33 (0.14–0.80) | – – – – |
|                        | Q3: 23.18–31.55 ng/dl | Q4: > 31.55 ng/dl | Q4 1.33 (1.07–1.66) | – | – – – – |
| Krijthe et al. (29), Netherlands | DHEAS quartiles | Age, sex, SBP, diastolic blood pressure, blood pressure lowering therapy, BMI, total and high density lipoprotein (HDL) cholesterol, smoking status, alcohol use, sex hormone therapy, prevalent myocardial infarction, heart failure and DM at baseline, and carotid plaque score | DHEAS | Q1 1 | – | 1 – |
|                        | Q1: 0.01–1.73 mmol/L | Q2 0.88 (0.46–1.70) | Q2 0.74 (0.39–1.32) | 0.74 (0.39–1.32) | – – – – |
|                        | Q2: 1.74–2.95 mmol/L | Q3 0.68 (0.34–1.39) | Q3 0.67 (0.34–1.34) | 0.67 (0.34–1.34) | – – – – |
|                        | Q3: 2.96–4.74 mmol/L | Q4 0.42 (0.19–0.96) | Q4 0.33 (0.14–0.80) | 0.33 (0.14–0.80) | – – – – |
|                        | Q4: 4.75–23.08 mmol/L | (Continued) | (Continued) | (Continued) | (Continued) |
### TABLE 3 Continued

| Reference, country | Exposure details | Confounding factor for multivariable analyses | Specific sex hormone | Effect estimator | Transformation of effect estimator |
|------------------|-----------------|---------------------------------------------|---------------------|----------------|----------------------------------|
|                 |                 |                                             |                     | Men            | Women                           |
| Magnani et al.   | Testosterone: a standard clinical threshold, 300 ng/dl per SD decrease | Smoking, BMI, SBP, hypertension treatment, diabetes mellitus, PR interval, significant murmur, and prevalent heart failure | Total testosterone | HR (95% CI) | P-value |
| United States    |                 |                                             |                     | 1.30 (1.07–1.59) | 0.008 |
|                  |                 |                                             |                     | 1.14 (0.91–1.44) | 0.26 |
|                  |                 |                                             |                     | 3.53 (1.96–6.37) | <0.0001 |
|                  |                 |                                             | Estradiol Per SD decrease | 1.12 (1.01–1.26) | 0.04 |
|                  |                 |                                             | DHEAS Per SD decrease | 1.12 (0.99–1.28) | 0.08 |
| O’Neal et al.    | TT: T3 vs. T1, BT: T3 vs. T1 | Age, race, education, income, current smoking, study site, diabetes, systolic blood pressure, height, BMI, aspirin, antihypertensive medications, lipid-lowering therapies, and left ventricular hypertrophy | Total testosterone | 1.12 (0.87–1.45) | 0.36 |
| United States    | Estradiol: T3 vs. T1, SHBG: T3 vs. T1 | Diabetes, systolic blood pressure, height, BMI, aspirin, antihypertensive medications, lipid-lowering therapies, and left ventricular hypertrophy | BT | 1.06 (0.97–1.16) | 0.041 |
|                  |                 |                                             | Estradiol | 0.96 (0.75–1.24) | 0.71 |
|                  |                 |                                             | SHBG | 0.96 (0.90–1.03) | 0.36 |
| Zeller et al.    | TT per one nmol/L increase | Age was used as time-scale, adjusted for geographical region, total cholesterol (log), HDL-C (log), systolic blood pressure (log), hypertension medication, known diabetes, smoking status, waist-hip ratio, and time of day of the blood draw | Total testosterone | 0.98 (0.97–1.00) | 0.049 |

**Notes:**
- The overall effect estimates were calculated using the inverse variance method.
- The reciprocal of the original effect value was used to calculate the effect estimate by comparing the highest and lowest categories.
- BMI, body mass index; BT, bioavailable testosterone; CI, confidence interval; DHEAS, dehydroepiandrosterone sulfate; DHT, dihydrotestosterone; DM, diabetes mellitus; HDL-C, high-density lipoprotein cholesterol; HR, hazard ratio; IST, ischemic stroke; LV, left ventricular; NT-proBNP, N-terminal pro-B-type natriuretic peptide; RIA, radioimmunoassay; SBP, systolic blood pressure; SHBG, sex hormone binding globulin; TT, total testosterone.

---

**References:**
- Magnani et al. (20)
- O’Neal et al. (21)
- Zeller et al. (17)
women. Similarly, the risk of AF was not associated with serum estradiol in men.

The pooled results in this study indicated that a high DHEAS level was associated with a 27.1% reduced AF risk in men. A negative association between DHEAS level and the risk of heart failure and mortality in both genders was found in a cohort study with 8,143 participants (33). Lower DHEAS concentration was also found to be associated with a higher risk of cardiovascular mortality (34, 35) and prognosis (36). Besides, DHEAS was inversely associated with sex-dependent diverse carotid atherosclerosis (37–39), and subjects with carotid atherosclerosis were at high risk of developing AF (40). The possible mechanisms may be due to the reason that DHEAS has the property of anti-inflammation (41, 42), which can influence the occurrence of AF (43). A pathological study has shown that the zona reticularis, responsible for most DHEAS production, seems to be more vulnerable to vascular damage (44). DHEAS can inhibit vascular remodeling by reducing
TABLE 5 Subgroup analysis for the association of total testosterone and atrial fibrillation risk in men.

| Subgroups | No. | Pooled RR (95% CI) | P<sub>h</sub> | I2 (%) |
|-----------|-----|-------------------|------------|--------|
| All       | 4   | 1.008 (0.799–1.273) | 0.000      | 83.1   |
| Region    |     |                   |            |        |
| United States | 3 | 1.017 (0.674–1.533) | 0.001      | 86.2   |
| Non-United States | 1 | 0.957 (0.926–0.989) | –          | –      |
| Age       |     |                   |            |        |
| <63 years | 2   | 1.033 (0.838–1.274) | 0.085      | 66.3   |
| ≥63 years | 2   | 0.923 (0.443–1.926) | 0.000      | 92.8   |
| BMI       |     |                   |            |        |
| <27.5 kg/m² | 2 | 0.801 (0.533–1.205) | 0.013      | 84.0   |
| ≥27.5 kg/m² | 2 | 1.273 (1.078–1.504) | 0.549      | 0.0    |
| TT assessment |   |                   |            |        |
| RIA       | 2   | 0.876 (0.464–1.651) | 0.002      | 89.2   |
| Others    | 2   | 1.107 (0.804–1.526) | 0.004      | 88.2   |

BMI, body mass index; RIA, radioimmunoassay; others, liquid chromatography-tandem mass spectrometry, chemiluminescence method, chemiluminescent microparticle immunoassay.

The evidence investigating the association between TT level and the risk of AF was contradictory, no matter in the included cohort studies or case-control studies (17, 18, 20–22, 30, 32). The meta-analysis of cohort studies showed that AF risk was not associated with TT concentration in men and post-menopausal women, respectively, and AF risk was not associated with estradiol concentration in men in all two case-control studies and one cohort study (21, 22, 32). Similarly, other studies with meta-analysis did not demonstrate any significant association of TT and estradiol levels with cardiovascular disease risk in men and post-menopausal women (19, 45, 46). The Framingham Heart Study found that older men with decreased testosterone levels were at an increased AF risk, while Berger et al. found that a higher TT level was associated with an increased risk of AF in men, and the Multi-Ethnic Study of Atherosclerosis (MESA) found that TT level was not associated with AF risk in men. The different results of the studies may be related to the variation in the study populations examined among the studies; the men in the Framingham Heart Study were Caucasian and much older, while the Atherosclerosis Risk in Communities (ARIC) study and the MESA included populations of different races. Some important factors in the included studies may also cause the discrepancies, such as different numbers of included participants, the age difference of the participants in the studies, and various follow-up periods in the cohort studies. A recent study showed that after testosterone replacement therapy, the normalization of testosterone levels is associated with decreased AF incidence (47). However, the heterogeneity was relatively high among different studies, so more longitudinal studies with multiple monitoring or studies that include AF as an endpoint in clinical trials are needed to promulgate the association of AF incidence with TT and estradiol concentration.

There were insufficient studies to examine the association between the level of DHT, BT, and SHBG and AF risk. In the

neointima formation after vascular injury, thereafter reducing vascular inflammation (38).

The evidence investigating the association between TT level and the risk of AF was contradictory, no matter in the included cohort studies or case-control studies (17, 18, 20–22, 30, 32). The meta-analysis of cohort studies showed that AF risk was not associated with TT concentration in men and post-menopausal women, respectively, and AF risk was not associated with estradiol concentration in men in all two case-control studies and one cohort study (21, 22, 32). Similarly, other studies with meta-analysis did not demonstrate any significant association of TT and estradiol levels with cardiovascular disease risk in men and post-menopausal women (19, 45, 46). The Framingham Heart Study found that older men with decreased testosterone levels were at an increased AF risk, while Berger et al. found that a higher TT level was associated with an increased risk of AF in men, and the Multi-Ethnic Study of Atherosclerosis (MESA) found that TT level was not associated with AF risk in men. The different results of the studies may be related to the variation in the study populations examined among the studies; the men in the Framingham Heart Study were Caucasian and much older, while the Atherosclerosis Risk in Communities (ARIC) study and the MESA included populations of different races. Some important factors in the included studies may also cause the discrepancies, such as different numbers of included participants, the age difference of the participants in the studies, and various follow-up periods in the cohort studies. A recent study showed that after testosterone replacement therapy, the normalization of testosterone levels is associated with decreased AF incidence (47). However, the heterogeneity was relatively high among different studies, so more longitudinal studies with multiple monitoring or studies that include AF as an endpoint in clinical trials are needed to promulgate the association of AF incidence with TT and estradiol concentration.

There were insufficient studies to examine the association between the level of DHT, BT, and SHBG and AF risk. In the

neointima formation after vascular injury, thereafter reducing vascular inflammation (38).

The evidence investigating the association between TT level and the risk of AF was contradictory, no matter in the included cohort studies or case-control studies (17, 18, 20–22, 30, 32). The meta-analysis of cohort studies showed that AF risk was not associated with TT concentration in men and post-menopausal women, respectively, and AF risk was not associated with estradiol concentration in men in all two case-control studies and one cohort study (21, 22, 32). Similarly, other studies with meta-analysis did not demonstrate any significant association of TT and estradiol levels with cardiovascular disease risk in men and post-menopausal women (19, 45, 46). The Framingham Heart Study found that older men with decreased testosterone levels were at an increased AF risk, while Berger et al. found that a higher TT level was associated with an increased risk of AF in men, and the Multi-Ethnic Study of Atherosclerosis (MESA) found that TT level was not associated with AF risk in men. The different results of the studies may be related to the variation in the study populations examined among the studies; the men in the Framingham Heart Study were Caucasian and much older, while the Atherosclerosis Risk in Communities (ARIC) study and the MESA included populations of different races. Some important factors in the included studies may also cause the discrepancies, such as different numbers of included participants, the age difference of the participants in the studies, and various follow-up periods in the cohort studies. A recent study showed that after testosterone replacement therapy, the normalization of testosterone levels is associated with decreased AF incidence (47). However, the heterogeneity was relatively high among different studies, so more longitudinal studies with multiple monitoring or studies that include AF as an endpoint in clinical trials are needed to promulgate the association of AF incidence with TT and estradiol concentration.

There were insufficient studies to examine the association between the level of DHT, BT, and SHBG and AF risk. In the
Cardiovascular Health Study in the United States with a median follow-up of 9.5 years, Rosenberg et al. found that men with serum-free DHT of less than 0.16 ng/dl were associated with a 1.48-fold risk of AF in men when compared with those with higher levels of DHT (28). By using data from the MESA in the United States and with a median follow-up of 10.9 years, O’Neal et al. examined the roles of serum levels of estradiol, BT, and SHBG in the development of AF (21); when comparing the highest with the lowest tertiles, serum BT was associated with a 32% increased risk of AF in men, whereas no association was observed in post-menopausal women (21); serum estradiol was not associated with AF risk in men and post-menopausal women (21); serum SHBG was not associated with any AF risk in men and women (21). Magnani et al. found that a 1-SD decrease in estradiol was associated with an increased risk of AF in men (20). Different sample sizes, age differences, and different confounding factors that the studies considered may lead to different results. However, these results should be verified in more studies with a delicate and rigorous longitudinal design.

The potential pathophysiology underlying the association between sex hormones and AF is complex. In rats, androgens depress spontaneous depolarization during atrial pacemaking, resulting in acute vasodilation, increased contractility, and an increased sino-atrial recovery time (48). Androgens can lead to a larger response to inotropes in male atria by a post-synaptic increase in intracellular cAMP and are independent of beta-1 adrenoceptors (49). Estrogens are those that drive the sensitivity to catecholamine by downregulating the beta-1 receptors depending on the estrous cycle, in female mice (50). Animal experiments showed that the increased release of atrial natriuretic peptide that resulted from cardiac overload was reduced by testosterone (51). Altered atrial electrophysiology may also provide a possible mechanism for the association between sex hormones and AF. Animal models have shown that atrial electrophysiology is changed via experimental modification of systemic hormones. Compared with controls, orchietomized rats demonstrated greater repetitive atrial responses with left atrial pacing (52).
There were some limitations in the included studies. Almost all the included studies assessed the levels of circulating sex hormones at a single point in time; however, the longitudinal changes in the circulating level of sex hormones and whether these changes influenced the incidence of AF were unknown. The study by Berger et al. cannot avoid the effects of asymptomatic AF cases that may be missed in an outpatient setting, and false-negative misclassification may have occurred (18). Magnani et al.'s study (20) focused on middle-aged to older men in Europe, which cannot offer generalizability to younger people, women, and other races. The findings of O’Neal et al. (21) and Zeller et al. (17) did not include some important risk factors such as left atrial diameter and thyroid function, which may influence the results. The studies by Zeller et al. (17) and Berger et al. (18) only measured the levels of TT; however, TT includes SHBG and free testosterone, and the change in SHBG levels may cause the change in TT levels. The confounding factors considered in each included study were different, which may also cause the relatively high heterogeneity across the studies. For example, Krijthe et al. (29) and Zeller et al. (17) took total cholesterol and high-density lipoprotein cholesterol as two major confounding factors, while the other studies did not; Magnani et al. (20) considered PR interval and significant murmur as potential confounders, while the others did not; Berger et al. (18) included estimated glomerular filtration rate as a potential confounding factor, while the others did not.

The advantage of this study is that different sex hormones were fully considered, and for the first time, a qualitative systematic review with a quantitative meta-analysis was conducted to reveal the relationship between sex hormones and AF. The meta-analysis and sensitivity analysis were performed successively, and the results indicated the robustness and stability of the main results. Nevertheless, some limitations should be acknowledged in our study. First, specific sex hormones were measured by different methods, which may lead to information bias and thus may affect the consistency of the results; however, sensitivity analysis was repeated by omitting one study each time, and no significant change in pooled results was observed. Second, this study did not differentiate the AF types when doing the meta-analysis, so the effect of sex hormones on different types of AF needs further evaluation. Third, there were only six studies included; only two studies could be pooled to reveal the association of DHEAS and estradiol with AF risk in men, respectively; pooling results from limited evidence may influence the stability of our results to draw strong conclusions on the association between sex hormones and AF risk. Fourth, the potential heterogeneity among the included studies may exist in terms of population source, sample size, and subject characteristics; however, due to the limited data, the subgroup analysis and meta-regression based on these factors could not be performed for TT in women, estradiol in women, and DHEAS in men.

Conclusion

The findings of this systematic review and meta-analysis indicate that a higher endogenous DHEAS level was associated with a lower AF risk in men, whereas no association was observed between TT and estradiol concentration and AF risk. Longitudinal studies with multiple monitoring are needed to further promulgate the relationship between various circulating sex hormones and AF risk.

Data availability statement

Publicly available datasets were analyzed in this study. The data is available by contacting the corresponding authors or extracting from the original published research.

Author contributions

XL and HD conceived, designed, and supervised the study. PH and WZ searched the data. PH analyzed the data. PH and JH drafted the manuscript. PH, MZ, HD, WZ, HL, YL, and XL reviewed and interpreted the findings. All co-authors provided comments and approved the final version.

Funding

This research was funded by the National Key R&D Program of China (No. 2018YFE0208000), the Guangdong Provincial Key R&D Program (No. 2019B020230004), the Medical Science and Technology Research Fund of Guangdong Province (No. A2021129), the Science and Technology Program of Guangzhou City (No. 202102080404), and the Guangdong Basic and Applied Basic Research Foundation (No. 2022A1515010686). The funders had no role in the design, analysis, or writing of this manuscript.

Acknowledgments

We would like to show our thanks to the authors of the original published research; their achievements are the prerequisites of our study. We would also like to thank Zuyao Yang for his advice in improving the quality of the manuscript.
Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2022.952430/full#supplementary-material

References

1. Chugh S, Hamvoeller R, Narayanan K, Singh D, Rienstra M, Benjamin E, et al. Worldwide epidemiology of atrial fibrillation. A Global Burden of Disease 2010 Study. Circulation. (2014) 129:837–47. doi: 10.1161/CIRCULATIONAHA.113.055119

2. Lippi G, Sanchis-Gomar F, Cerrelli G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. Int J Stroke. (2021) 16:217–21. doi: 10.1177/1747493019897870

3. Pistola E, Sacco S, Tiseo C, Degan D, Ornello R, Carolei A. The epidemiology of atrial fibrillation and stroke. Cardiol Clin. (2016) 34:255–68. doi: 10.1016/j.ccl.2015.12.002

4. Emdin CA, Wong CX, Hsiiao AJ, Altman DG, Peters SA, Woodward M, et al. Atrial fibrillation as risk factor for cardiovascular disease and death in women compared with men: Systematic review and meta-analysis of cohort studies. BMJ (Clin Res Ed). (2016) 532:h7013. doi: 10.1136/bmj.h7013

5. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: The Rotterdam study. Eur Heart J. (2006) 27:949–53. doi: 10.1093/eurheartj/hbj825

6. Guo Y, Tian Y, Wang H, Si Q, Wang Y, Lip G. Prevalence, incidence, and lifetime risk of atrial fibrillation in China. New insights into the global burden of atrial fibrillation. Chest. (2015) 147:109–19. doi: 10.1378/chest.14-0321

7. Mandalenakis Z, Von Koch L, Eriksson H, Dellborg M, Caidahl K, Welin L, et al. The risk of atrial fibrillation in the general male population: A lifetime follow-up of 50-year-old men. Europace. (2015) 17:1018–22. doi: 10.1093/europace/euv036

8. Odening KE, Deiss S, Dilling-Boer D, Didenko M, Eriksson U, Nedosi S, et al. Mechanisms of sex differences in atrial fibrillation: Role of hormones and differences in electrophysiology, structure, function, and remodelling. Europace. (2019) 21:366–76. doi: 10.1093/europace/euy215

9. Westerman S, Wenger N. Gender differences in atrial fibrillation: A review of epidemiology, management, and outcomes. Circ Cardiol Rev. (2019) 15:136–44. doi: 10.21037/circrev.2019.03.015

10. Wang L, Suklo M, Folsom AR, Cook NR, Gasparrini SM, Ouyang P. Endogenous sex hormones, blood pressure change, and risk of hypertension in postmenopausal women: The multi-ethnic study of atherosclerosis. JAMA. (2012) 328:136–67. doi: 10.1001/jama.2012.153718

11. Bagletto L, English DR, Hopper JL, Macnfin RJ, Norris HA, Tilley WD, et al. Circulating steroid hormone concentrations in postmenopausal women in relation to body size and composition. Breast Cancer Res Treat. (2009) 115:171–9. doi: 10.1007/s10549-008-0069-3

12. Meongraw-Chaflin ML, Anderson CA, Allison MA, Ouyang P, Suklo M, Vaidya D, et al. Association between sex hormones and adiposity: Qualitative differences in women and men in the multi-ethnic study of atherosclerosis. J Clin Endocrinol Metab. (2015) 100:E596–600. doi: 10.1207/s10565623jcem.100.020423

13. Ding EL, Song Y, Manson JE, Spiegelman D, Travis RC, Liu S, et al. Plasma sex steroid hormone concentrations in postmenopausal women. J Clin Endocrinol Metab. (2009) 94:4127–35. doi: 10.1210/jc.2009-0910

14. Kalyani RR, Franco M, Dobs AS, Ouyang P, Vaidya D, Bertoni A, et al. The association of endogenous sex hormones, adiposity, and insulin resistance with incident diabetes in postmenopausal women. J Clin Endocrinol Metab. (2009) 94:1427–35. doi: 10.1210/jc.2009-0910

15. Goldstein J, Sites CK, Toth MJ. Progesterone stimulates cardiac muscle protein synthesis via receptor-dependent pathway. Fertil Steril. (2004) 82:430–6. doi: 10.1016/j.fertnstert.2004.03.018

16. Lizzetto E, Grandy SA, Tremblay A, Allen BG, Fiset C. Expression, distribution and regulation of sex steroid hormone receptors in mouse heart. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol. (2009) 23:75–86. doi: 10.1515/cpb.2009.006

17. Zeller T, Schnabl BR, Appelbaum S, Ojeda F, Bertsha F, Schulte-Steinberg B, et al. Low testosterone levels are predictive for incident atrial fibrillation and ischaemic stroke in men, but protective in women - results from the FINRISK study. Eur J Prev Cardiol. (2018) 25:1133–9. doi: 10.1177/2047487318787346

18. Berger D, Folsom AR, Schreiner PJ, Chen LY, Mischuc ED, O’Neal WT, et al. Plasma total testosterone and risk of incident atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study. Maturitas. (2019) 125:5–10. doi: 10.1016/j.maturitas.2019.03.015

19. Vandenplas G, De Bacquer D, Calders P, Fiers T, Kaufman JM, Ouwens DM, et al. Endogenous oestradiol and cardiovascular disease in healthy men: A systematic review and meta-analysis of prospective studies. Heart (Br Heart Joc). (2012) 98:1478–82. doi: 10.1136/heartjnl-2011-301587

20. Magnani JW, Moser CB, Murabito JM, Sullivan LM, Wong N, Ellison PT, et al. Association of sex hormones, aging, and atrial fibrillation in men: The Framingham Heart Study. Circ Arrhythmia Electrophysiol. (2014) 7:307–12. doi: 10.1161/CIRCEP.113.001322

21. O’Neal WT, Nazarian S, Alonso A, Heckbert SR, Vaccarino V, Solomon EZ. Sex hormones and the risk of atrial fibrillation: The Multi-Ethnic Study of Atherosclerosis (MESA). Endocrine. (2017) 58:91–6. doi: 10.1007/s12020-017-1385-3

22. Lai J, Zhou D, Xia S, Shang Y, Want L, Zheng L, et al. Reduced testosterone levels in males with lone atrial fibrillation. Clin Cardiol. (2009) 32:43–6. doi: 10.1002/cc.20423

23. Stroup D, Berlin J, Morton S, Olkin I, Williamson G, Rennie D, et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. (2000) 283:2008–12. doi: 10.1001/jama.283.15.2008

24. Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-Analyses of Observational Studies in Epidemiology (MOOSE) group. JAMA. (2000) 283:2008–12. doi: 10.1001/jama.283.15.2008

25. Cooper HM, Hedges LV, Valentine JC. The handbook of research synthesis. 2nd ed. New York, NY: Russell Sage Foundation (2019). doi: 10.7758/9781610448964.4

26. Danesh J, Collins R, Appleby P, Petro R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: Meta-analyses of prospective studies. JAMA. (1998) 279:1477–82. doi: 10.1001/jama.279.18.1477

27. Higgins J, Thompson S, Deeks J, Altman D. Measuring inconsistency in meta-analyses. 3rd ed. New York, NY: Russell Sage Foundation (2019). doi: 10.7758/9781610448964.4

28. Rosenberg MA, Shires MM, Matsumoto AM, Bukiková P, Lange LA, Kronmal RA, et al. Serum androgens and risk of atrial fibrillation in older men: The Cardiovascular Health Study. Clin Cardiol. (2018) 41:830–6. doi: 10.1002/clc.22965
in postmenopausal women with type 2 diabetes mellitus. Endocrine J. S, et al. Serum DHEA-S level is associated with the presence of atherosclerosis. Atherosclerosis. 5.011 (2010) 212:310–5. doi: 10.1016/j.atherosclerosis.2010.0130

Jia X, Sun C, Tang O, Gorlov I, Nambu V, Virani SS, et al. Plasma dehydroepiandrosterone sulfate and cardiovascular disease risk in older men and women. J Clin Endocrinol Metab. (2020) 105:e4304–27. doi: 10.1210/clinems.dgaas518

Ohlsson C, Labrie F, Barrett-Connor E, Karlsson MK, Ljunggren O, Vandeput L, et al. Low serum levels of dehydroepiandrosterone sulfate predict all-cause and cardiovascular mortality in elderly Swedish men. J Clin Endocrinol Metab. (2010) 95:4406–14. doi: 10.1210/jc.2010-0760

Shufelt C, Brezitsky P, Almeida CM, Johnson BD, Shaw LJ, Aziza R, et al. DHEA-S levels and cardiovascular disease mortality in postmenopausal women: Results from the National Institutes of Health—National Heart, Lung, and Blood Institute (NHLBI)-sponsored Women’s Ischemia Syndrome Evaluation (WISE). J Clin Endocrinol Metab. (2010) 95:4985–92. doi: 10.1210/jc.2010-0143

Wu TT, Chen Y, Zhou Y, Adi D, Zheng YY, Liu F, et al. Prognostic value of dehydroepiandrosterone sulfate for patients with cardiovascular disease: A systematic review and meta-analysis. J Am Heart Assoc. (2017) 6:e004896. doi: 10.1161/JAHA.116.004896

Yoshida S, Aihara K-I, Azuma H, Uemoto R, Sumitomo-Ueda Y, Yagi S, et al. Dehydroepiandrosterone sulfate is inversely associated with sex-dependent diverse carotid atherosclerosis regardless of endothelial function. Atherosclerosis. (2010) 212:310–5. doi: 10.1016/j.atherosclerosis.2010.05.011

Isi M, Hoshiga M, Negoro N, Fukui R, Nakakoji T, Kobayashi E, et al. Adrenal androgen dehydroepiandrosterone sulfate inhibits vascular remodeling following arterial injury. Atherosclerosis. (2009) 206:77–85. doi: 10.1016/j.atherosclerosis.2009.02.021

Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Kurioka S, Yano S, et al. Serum DHEA-S level is associated with the presence of atherosclerosis in postmenopausal women with type 2 diabetes mellitus. Endocrine J. (2008) 55:667–75. doi: 10.1507/endocr.JOTE.130

Willett K, Pechlaner R, Egger G, Weger S, Oberhollenzer M, Willett J, et al. Carotid atherosclerosis and incident atrial fibrillation. Arterioscler Thromb Vasc Biol. (2013) 33:2660–5. doi: 10.1161/ATVBAHA.113.302272

Chen CC, Parker CR Jr. Adrenal androgens and the immune system. Semin Reprod Med. (2002) 20:369–77. doi: 10.1055/s-2004-661553

Arlt W, Hewison M. Hormones and immune function. Implications of ageing. Ageing Cell. (2004) 3:209–16. doi: 10.1111/j.1474-9728.2004.00109.x

Schoonderwoerd BA, Smit MD, Pen L, Van Gelder IC. New risk factors for atrial fibrillation: Causes of ‘not-so-lone atrial fibrillation’. Europace. (2008) 10:668–73. doi: 10.1093/europace/eun124

Angeli A, Masera RG, Magni F, Ferrari E. The adrenal cortex in physiological and pathological aging: Issues of clinical relevance. J Endocrinol Invest. (1999) 22:13–8.

Wang H, Li Y, Wang X, Bu J, Yan G, Lou D. Endogenous sex hormone levels and coronary heart disease risk in postmenopausal women: A meta-analysis of prospective studies. Eur J Prevent Cardiol. (2017) 24:600–11. doi: 10.1177/2047487317693133

Ruige JB, Mahmoud AM, De Bacquier D, Kaufman JM. Endogenous testosterone and cardiovascular disease in healthy men: A meta-analysis. Heart (Br Cardiovsc Soc). (2011) 97:870–5. doi: 10.1136/hrt.2010.210757

Sharma R, Oni OA, Gupta K, Sharma M, Sharma R, Singh V, et al. Normalization of testosterone levels after testosterone replacement therapy is associated with decreased incidence of atrial fibrillation. J Am Heart Assoc. (2017) 6:e004880. doi: 10.1161/JAHA.116.004880

Sánchez M, Secades L, Bordallo C, Meana C, Rubin JM, Cantabrana B, et al. Role of polyamines and cAMP-dependent mechanisms on Salpba-dihydrotestosterone-elicited functional effects in isolated right atria of rat. J Cardiovasc Pharmacol. (2009) 54:310–8. doi: 10.1097/FJC.0b013e3181be57f

Velasco L, Sánchez M, Rubin JM, Hidalgo A, Bordallo C, Cantabrana B. Intracellular cAMP increases during the positive inotropism induced by androgens in isolated left atrium of rat. Eur J of Pharmacol. (2002) 438:45–52. doi: 10.1016/S0014-2999(02)01300-6

Kocić I, Gruchala M, Petrušević J. Pretreatment of male guinea pigs by 17-beta-estradiol induces hypersensitivity of beta-adrenoceptors in electrically driven left atria. Int J Cardiol. (2008) 129:22–5. doi: 10.1016/j.ijcard.2007.05.040

Deng Y, Kaufman S. The influence of reproductive hormones on ANF release by rat atria. Life Sci. (1993) 53:689–96. doi: 10.1016/0024-3205(93)90245-X

Tsuneeda T, Yamashita T, Kato T, Sekiguchi A, Sagara K, Sawada H, et al. Deficiency of testosterone associates with the substrate of atrial fibrillation in the rat model. J Cardiovasc Electrophysiol. (2009) 20:1055–60. doi: 10.1111/j.1540-8167.2009.01474.x